Future Proofing Drug Safety: Target Carcinogenicity Risk Assessment Meets ICH S1B(R1) Standards

Let’s re-imagine the carcinogenicity assessment In the fast-paced and cost-conscious ‘drug to market’ race, momentum can be gained by implementing a Weight of Evidence (WoE) to negate unnecessary preclinical testing. We will present results from a collaboration to standardize a procedural framework supporting the ICH S1B(R1) integrated assessment. Specifically, target biology (WoE #1) will be presented. This is the concise version of the presentation that was originally shared at the 2024 Annual SOT Meeting and ToxExpo.

Let’s re-imagine the carcinogenicity assessment

In the fast-paced and cost-conscious ‘drug to market’ race, momentum can be gained by implementing a Weight of Evidence (WoE) to negate unnecessary preclinical testing. We will present results from a collaboration to standardize a procedural framework supporting the ICH S1B(R1) integrated assessment. Specifically, target biology (WoE #1) will be presented.

This is the concise version of the presentation that was originally shared at the 2024 Annual SOT Meeting and ToxExpo.

Get This Resource

Share This Resource